University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.
Complete findings are printed in today's issue of the Journal of Virology.
The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2'-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis. Lethal mutagenesis annihilates HIV by causing it to mutate to the point of extinction.
The compound 3-deazauridine stopped HIV by creating so many mutations in the virus that the virus was no longer able to spread throughout the body by infecting other cells. The other compounds caused early termination of HIV DNA synthesis, again preventing the virus from being able to reproduce. Studies prior to this one determined certain ribonucleosides analogs impact HIV DNA synthesis, a process called reverse transcription. The extent to which they worked was not previously known.
"It's a counterintuitive finding," said University of Minnesota virologist Louis Mansky, Ph.D. "These ribonucleoside analogs were not generally thought to be associated with affecting HIV DNA synthesis – a critical step in virus replication. We don't yet know all the details for how these particular compounds stop the virus in its path."
The research, if translatable, will provide a potentially cost-effective and fresh treatment option to counter HIV's rapid evolution and treat HIV resistance to currently approved anti-HIV drugs. Anti-HIV ribonucleoside analogs are less expensive to create in a laboratory than deoxyribonucleoside analogs, which are key in drugs currently used to stop HIV replication and cell spread. Additionally, the similarity of ribonucleoside analogs to deoxyribonucleosides may help speed up the development process to make full use of this target as a wealth of understanding around ribonucleoside analogs already exists.
Explore further: Viral replication may not be primary cause of HIV-1 persistence in patients receiving cART
Medical Xpress on facebook
Related Stories
Viral replication may not be primary cause of HIV-1 persistence in patients receiving cART
Nov 26, 2013
(Medical Xpress)—A team of researchers with members from Europe and the U.S. has found that viral replication may not be the main reason that the HIV virus is able to persist in the cells of infected patients ...
France okays home tests for HIV
Nov 07, 2013
Self-testing HIV kits will go on sale in France next year under a strategy aimed at reducing the spread of the virus causing AIDS, Health Minister Marisol Touraine said on Thursday.
Drug design success propels efforts to fight HIV with a combination of two FDA-approved drugs
Aug 30, 2013
A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved ...
Scientists find the invisibility cloak that shields HIV-1 from the immune system
Nov 21, 2013
Of the two major types of HIV, only one, HIV-1, typically causes AIDS in infected people who don't receive treatment. A study published by Cell Press November 21st in the journal Immunity reveals how HIV-1 ...
Nail fungus drug might help against HIV, study suggests
Sep 24, 2013
(HealthDay)—A common drug used to treat nail fungus may hold promise against HIV, the virus that causes AIDS, according to a new study.
Recommended for you
Animal vaccine study yields insights that may advance HIV vaccine research
1 hour ago
A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights ...
Secondary conditions affect length of hospital stay and charges for HIV patients
Dec 16, 2013
A University of Arkansas researcher and her colleagues have found that secondary conditions and diseases that could become deadly significantly affect how long HIV patients stay in the hospital.
Plaque composition, immune activation explain cardiovascular risk in HIV-infected women
Dec 13, 2013
A Massachusetts General Hospital (MGH) research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men. In ...
Hemophilia and long-term HIV infection—is there a protective link?
Dec 11, 2013
People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective ...
Spanish hospital to trial new HIV treatment
Dec 09, 2013
Researchers at a Spanish hospital announced Monday they will start trials next year of a therapeutic vaccine for patients who already have HIV, the virus that causes AIDS.
HIV/AIDS prevalence and prospects
Dec 09, 2013
In the more than two decades that psychology professor Seth Kalichman has devoted to HIV/AIDS prevention, he has seen the public health landscape change dramatically. This is what he had hoped for when, as a graduate student ...
User comments
© Medical Xpress 2011-2013, Science X network
University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.
Complete findings are printed in today's issue of the Journal of Virology.
The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2'-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis. Lethal mutagenesis annihilates HIV by causing it to mutate to the point of extinction.
The compound 3-deazauridine stopped HIV by creating so many mutations in the virus that the virus was no longer able to spread throughout the body by infecting other cells. The other compounds caused early termination of HIV DNA synthesis, again preventing the virus from being able to reproduce. Studies prior to this one determined certain ribonucleosides analogs impact HIV DNA synthesis, a process called reverse transcription. The extent to which they worked was not previously known.
"It's a counterintuitive finding," said University of Minnesota virologist Louis Mansky, Ph.D. "These ribonucleoside analogs were not generally thought to be associated with affecting HIV DNA synthesis – a critical step in virus replication. We don't yet know all the details for how these particular compounds stop the virus in its path."
The research, if translatable, will provide a potentially cost-effective and fresh treatment option to counter HIV's rapid evolution and treat HIV resistance to currently approved anti-HIV drugs. Anti-HIV ribonucleoside analogs are less expensive to create in a laboratory than deoxyribonucleoside analogs, which are key in drugs currently used to stop HIV replication and cell spread. Additionally, the similarity of ribonucleoside analogs to deoxyribonucleosides may help speed up the development process to make full use of this target as a wealth of understanding around ribonucleoside analogs already exists.
Explore further: Viral replication may not be primary cause of HIV-1 persistence in patients receiving cART
Medical Xpress on facebook
Related Stories
Viral replication may not be primary cause of HIV-1 persistence in patients receiving cART
Nov 26, 2013
(Medical Xpress)—A team of researchers with members from Europe and the U.S. has found that viral replication may not be the main reason that the HIV virus is able to persist in the cells of infected patients ...
France okays home tests for HIV
Nov 07, 2013
Self-testing HIV kits will go on sale in France next year under a strategy aimed at reducing the spread of the virus causing AIDS, Health Minister Marisol Touraine said on Thursday.
Drug design success propels efforts to fight HIV with a combination of two FDA-approved drugs
Aug 30, 2013
A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved ...
Scientists find the invisibility cloak that shields HIV-1 from the immune system
Nov 21, 2013
Of the two major types of HIV, only one, HIV-1, typically causes AIDS in infected people who don't receive treatment. A study published by Cell Press November 21st in the journal Immunity reveals how HIV-1 ...
Nail fungus drug might help against HIV, study suggests
Sep 24, 2013
(HealthDay)—A common drug used to treat nail fungus may hold promise against HIV, the virus that causes AIDS, according to a new study.
Recommended for you
Animal vaccine study yields insights that may advance HIV vaccine research
1 hour ago
A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights ...
Secondary conditions affect length of hospital stay and charges for HIV patients
Dec 16, 2013
A University of Arkansas researcher and her colleagues have found that secondary conditions and diseases that could become deadly significantly affect how long HIV patients stay in the hospital.
Plaque composition, immune activation explain cardiovascular risk in HIV-infected women
Dec 13, 2013
A Massachusetts General Hospital (MGH) research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men. In ...
Hemophilia and long-term HIV infection—is there a protective link?
Dec 11, 2013
People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective ...
Spanish hospital to trial new HIV treatment
Dec 09, 2013
Researchers at a Spanish hospital announced Monday they will start trials next year of a therapeutic vaccine for patients who already have HIV, the virus that causes AIDS.
HIV/AIDS prevalence and prospects
Dec 09, 2013
In the more than two decades that psychology professor Seth Kalichman has devoted to HIV/AIDS prevention, he has seen the public health landscape change dramatically. This is what he had hoped for when, as a graduate student ...
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment